Aevi genomic medicine, inc. (GNMX)
Income statement / Quarterly
Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Research and development expenses

-

2,234

3,169

4,866

-

5,747

6,561

5,263

6,299

5,667

7,947

5,135

7,725

8,741

6,951

5,429

4,568

4,458

3,901

4,112

2,281

1,955

2,142

2,314

2,452

2,073

2,031

2,062

1,894

1,639

1,592

1,484

1,785

1,544

1,174

1,011

811

Less: Participation by the Office of the Chief Scientist

-

-

-

-

-

-

-

-

-

-

-

-

196

-

-

-

-

-

-

-

716

1,182

-

246

109

1,218

0

-13

283

464

1,022

0

357

503

0

191

147

U.S. Government grant

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

0

0

Participation by third party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

75

0

0

385

-265

Research and development expenses

2,499

-

-

-

5,125

-

-

-

-

-

-

-

-

-

-

4,314

4,201

3,028

3,901

-

1,565

773

-

2,068

2,343

855

2,031

2,075

1,611

1,175

570

1,484

1,353

1,041

1,174

435

399

Non-recurring research and development expenses resulting from acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

8,170

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative expenses

1,543

1,415

1,685

1,811

2,174

2,504

2,174

1,897

2,270

2,369

2,988

3,345

3,042

2,945

4,191

2,122

2,996

3,889

3,947

2,424

2,305

2,864

3,093

3,826

2,561

1,588

2,546

1,594

1,470

2,774

1,359

1,215

1,877

1,052

780

2,616

441

Excess amount of participation in research and development from third party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

734

-688

Operating loss

-4,042

-3,649

-4,854

-6,677

-7,299

-8,251

-8,735

-7,160

-8,569

-8,036

-10,935

-8,480

-10,571

-11,686

-11,142

-6,436

-15,367

-6,917

-7,848

-6,197

-3,870

-3,637

-5,235

-5,894

-4,904

-2,443

-4,577

-3,669

-3,081

-3,949

-1,929

-2,699

-3,230

-2,093

-1,954

-2,317

-152

Financial income, net

0

4

15

-

50

60

26

-

-

-

-

-

14

-18

-2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financial expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

21

1,192

8

1,078

-333

64

217

120

-

1,260

25

-

-

-

-

-

-

-

-

-

-

-

Financial income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

44

843

5

-328

896

15

3

-

21

371

-

-

-

-

-

-

-

-

-

-

-

Financial expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

-

0

2,972

801

-

267

232

-

-

-

Financial income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

915

-

55

17

18

-

74

4

-

-

-

Financial expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

106

-2,199

1,830

Financial income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,722

-910

31

Loss before taxes on income

-

-

-

-

-

-

-

-

-

-

-

-

-10,557

-11,704

-

-

-

-

-

-6,192

-3,038

-3,839

-5,352

-5,196

-6,143

-2,097

-3,676

-2,410

-3,026

-6,904

-2,712

-2,011

-3,423

-2,321

-338

-3,606

-

Income (loss) before taxes on income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,951

Taxes on income

-

-

-

-

-

-

-

-

-

-

-

-

13

3

-

-

-

-

-

4

2

1

5

12

0

2

3

10

1

8

0

0

1

2

0

-

0

Net loss

-4,042

-3,645

-4,839

-6,626

-7,249

-8,191

-8,709

-7,159

-8,605

-8,033

-10,917

-8,483

-10,570

-11,707

-11,144

-6,463

-16,521

-6,086

-8,922

-6,196

-3,040

-3,840

-5,357

-5,208

-6,143

-2,099

-3,679

-2,420

-3,027

-6,912

-2,712

-2,011

-3,424

-2,323

-338

-3,606

-1,951

Basic and diluted loss per share

-0.06

-0.06

-0.07

-

-0.12

-0.14

-0.15

-

-

-

-

-

-0.29

-0.35

-0.34

-

-

-

-

-

-

-

-0.28

-

-

-

-

-

-0.25

-

-

-

-0.35

-0.26

-0.06

-0.80

-

Weighted average number of common stock used in computing basic and diluted loss per share

-

-

-

-

-

-

-

-

-

-

-

-

37,080

33,469

32,953

-

-

-

-

-

-

-

18,872

-

-

-

-

-

-

-

-

-

9,657

9,033

-

-

-

Basic loss per share

-

-

-

-0.10

-

-

-

-0.13

-0.23

-0.22

-0.29

-

-

-

-

-0.20

-0.66

-0.24

-0.36

-

-0.16

-0.21

-

-0.29

-0.33

-0.11

-0.24

-

-

-0.69

-0.28

-

-

-

-

-

-0.47

Diluted loss per share

-

-

-

-0.10

-

-

-

-0.13

-0.23

-0.22

-0.29

-

-

-

-

-0.20

-0.66

-0.28

-0.36

-

-0.21

-0.21

-

-0.33

-0.33

-0.11

-0.29

-

-

-0.69

-0.28

-

-

-

-

-

-0.47

Weighted average number of common stock used in computing basic and diluted loss per share

64,766

64,766

64,766

64,766

62,019

59,338

59,334

55,225

37,110

37,110

37,108

-

-

-

-

32,339

24,982

24,906

24,843

-

18,817

18,715

-

18,473

18,410

18,410

15,222

12,295

12,013

10,032

9,753

-

-

-

-

-

4,133

Weighted average number of shares of common stock used in computing diluted loss per share

-

-

-

64,766

-

-

-

55,225

37,110

37,110

37,108

-

-

-

-

32,339

24,982

25,094

24,843

-

18,938

18,715

-

18,277

18,410

18,410

15,634

12,295

12,013

10,032

9,753

-

-

-

-

-

4,133

Weighted average number of Common stock used in computing basic and diluted loss per share (in shares)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,370

4,534

-